This Article Abstract Full Text (PDF) All Versions of this Article: 110/1/51    most recent 01.CIR.0000133390.12306.C7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanada, S. Articles by Kitakaze, M. Search for Related Content PubMed PubMed Citation Articles by Sanada, S. Articles by Kitakaze, M. Related Collections Acute myocardial infarction Cardiovascular Pharmacology Animal models of human disease Cell signalling/signal transduction Ischemic biology - basic studies

(Circulation. 2004;110:51-57.)
© 2004 American Heart Association, Inc.

Original Articles

Protein Kinase A as Another Mediator of Ischemic Preconditioning Independent of Protein Kinase C

Shoji Sanada, MD, PhD; Hiroshi Asanuma, MD, PhD; Osamu Tsukamoto, MD; Tetsuo Minamino, MD, PhD; Koichi Node, MD, PhD; Seiji Takashima, MD, PhD; Tomi Fukushima, PhD; Akiko Ogai, PhD; Yoshiro Shinozaki, MD, PhD; Masashi Fujita, MD; Akio Hirata, MD; Hiroko Okuda, MD; Hiroaki Shimokawa, MD, PhD; Hitonobu Tomoike, MD, PhD; Masatsugu Hori, MD, PhD; Masafumi Kitakaze, MD, PhD

From the Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita; Cardiovascular Division (K.N.), Department of Medicine, Saga University Faculty of Medicine, Saga; Cardiovascular Division of Medicine (A.O., H.T., M.K.), National Cardiovascular Center, Suita; Department of Physiological Science (Y.S.), Tokai University School of Medicine, Isehara; and Department of Cardiovascular Medicine (H.S.), Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Correspondence to Masafumi Kitakaze, MD, PhD, Cardiovascular Division of Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, 565-8565 Japan. E-mail kitakaze{at}zf6.so-net.ne.jp

Received November 15, 2003; de novo received December 28, 2003; revision received March 10, 2004; accepted March 17, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— We and others have reported that transient accumulation of cyclic AMP (cAMP) in the myocardium during ischemic preconditioning (IP) limits infarct size independent of protein kinase C (PKC). Accumulation of cAMP activates protein kinase A (PKA), which has been demonstrated to cause reversible inhibition of RhoA and Rho-kinase. We investigated the involvement of PKA and Rho-kinase in the infarct limitation by IP.

Methods and Results— Dogs were subjected to 90-minute ischemia and 6-hour reperfusion. We examined the effect on Rho-kinase activity during sustained ischemia and infarct size of (1) preischemic transient coronary occlusion (IP), (2) preischemic activation of PKA/PKC, (3) inhibition of PKA/PKC during IP, and (4) inhibition of Rho-kinase or actin cytoskeletal deactivation during myocardial ischemia. Either IP or dibutyryl-cAMP treatment activated PKA, which was dose-dependently inhibited by 2 PKA inhibitors (H89 and Rp-cAMP). IP and preischemic PKA activation substantially reduced infarct size, which was blunted by preischemic PKA inhibition. IP and preischemic PKA activation, but not PKC activation, caused a substantial decrease of Rho-kinase activation during sustained ischemia. These changes were cancelled by preischemic inhibition of PKA but not PKC. Furthermore, either Rho-kinase inhibition (hydroxyfasudil or Y27632) or actin cytoskeletal deactivation (cytochalasin-D) during sustained ischemia achieved the same infarct limitation as preischemic PKA activation without affecting systemic hemodynamic parameters, the area at risk, or collateral blood flow.

Conclusions— Transient preischemic activation of PKA reduces infarct size through Rho-kinase inhibition and actin cytoskeletal deactivation during sustained ischemia, implicating a novel mechanism for cardioprotection by ischemic preconditioning independent of PKC and a potential new therapeutic target.

Key Words: ischemia • infarction • proteins

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The potent cardioprotection induced by brief periods of ischemia before sustained ischemia is termed ischemic preconditioning (IP). Previous studies^1–4 have exhibited some possible mediators of IP-derived cardioprotection, suggested to link with protein kinase C (PKC).^3,4 On the other hand, a brief preconditioning ischemia also induces a synchronized increase of the myocardial cyclic AMP (cAMP) level.⁵ Furthermore, we and others^5,6 have reported that brief preischemic exposure to ß-agonists, an adenylate cyclase activator, phosphodiesterase type III inhibitors, or a cell-permeable cAMP analogue, all of which cause rapid activation of protein kinase A (PKA), also protects the myocardium in vivo independently of PKC. However, little is known about the direct contribution of PKA to infarct limitation by IP and the associated subcellular mechanisms. Some recent studies have demonstrated that an increase of cAMP followed by activation of PKA causes temporary inhibition of small GTPase RhoA^7,8 and its downstream Rho-kinase,⁷ playing major roles in enhancement of actin cytoskeleton formation followed by chemotactic migration, platelet activation, and cytokinesis.^7,9 Therefore, we hypothesized that transient preischemic activation of PKA may also cause IP-induced infarct limitation through the inhibition of Rho-kinase after the onset of sustained ischemia. This study was designed to test this hypothesis in vivo.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
All procedures were performed in conformity with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, 1996 revision) and were approved by the Osaka University Committee for Laboratory Animal Use.

Instrumentation
As described previously,¹⁰ beagle dogs (Oriental Yeast; Osaka, Japan) weighing 9 to 14 kg were anesthetized with sodium pentobarbital (30 mg/kg IV) and connected to an extracorporeal bypass tube. In all experiments, the average control values of mean aortic blood pressure (ABP), heart rate (HR), and arterial blood pO₂ were 101±2.3 mm Hg, 127±2.4/minute, and 108±3.8 mm Hg, respectively. Both ABP and HR were measured continuously during the experiment.

Experimental Protocols
Protocol 1: Infarct Size After Preconditioning
Figure 1 shows the study protocol. After hemodynamic stabilization, 176 dogs underwent 90 minutes of ischemia and 6 hours of reperfusion with or without 1 or more of the following interventions: (1) 5-minute coronary occlusion followed by 25-minute reperfusion just before sustained ischemia (IP), (2) intracoronary administration of the potent PKC activator phorbol 12-myristate 13-acetate (PMA, Sigma; 0.62 ng/kg per min), or (3) an intravenous administration of the cell-permeable cAMP analogue dibutyryl-cAMP (db-cAMP, Sigma; 5 mg/kg over 5 minutes), in combination with (4) intracoronary injection of a selective PKC inhibitor, GF109203X (Calbiochem; 40 µg/kg per min) or 1 of 2 selective PKA inhibitors (H89^6,11 [Sigma; 1.35 µg/kg per min] or the Rp-isomer of cAMP¹² [Rp-cAMP, Calbiochem; 45 µg/kg per min]) or (5) infusion of vehicle (at a rate of 0.0167 mL/kg per min) (control, vehicle, IP, IP+vehicle, IP+H89, IP+Rp-cAMP, PMA, PMA+H89, PMA+Rp-cAMP, Db-cAMP, Db-cAMP+H89, Db-cAMP+Rp-cAMP, Db-cAMP+GF109203X [GFX], PMA+Db-cAMP, H89, Rp-cAMP, and GFX groups, respectively; n=8 to 13 each).

View larger version (43K): [in this window] [in a new window]   Figure 1. Protocols for measuring infarct size.

We used the same PMA or db-cAMP regimens that were used in our previous studies,^3,6 which demonstrated potent infarct limitation in this model. The regimen of GF109203X infusion was the same as that used in our previous study³ to blunt infarct limitation by IP and PMA.

Protocol 2: Infarct Size in the Inhibition Protocol During Ischemia
The lower part of Figure 1 shows the protocol. Sixty-six dogs underwent the same protocol for sustained ischemia-reperfusion with or without intracoronary administration of (1) a selective Rho-kinase inhibitor (hydroxyfasudil¹³ [Asahi-Kasei; 2.4 and 12 µg/kg per min] or Y27632¹⁴ [Welfide; 0.7 and 3.5 µg/kg per min]), (2) an actin cytoskeleton disruptor cytochalasin-D¹⁵ (Calbiochem; 5.1 µg/kg per min), or (3) vehicle (a small volume of DMSO, which does not affect infarct size in the same model¹⁰) between the onset and 60 minutes of sustained ischemia (hydroxyfasudil-lower dose [LD], hydroxyfasudil, Y27632-LD, Y27632, cytochalasin-D, and ischemia-vehicle groups, respectively; n=10 to 12 each).

The higher doses of hydroxyfasudil and Y-27632 for intracoronary infusion were the highest doses that could not influence systemic hemodynamics during our preliminary study in this model (data not shown).

Protocol 3: Tissue Kinase Assay
Figure 2 shows the protocol. Ninety dogs were subjected to sustained myocardial ischemia according the same method as in protocol 1 with or without (1) IP, (2) preischemic administration of db-cAMP or PMA, (3) preischemic administration of H89, Rp-cAMP, or GF109203X, or (4) administration of hydroxyfasudil or Y27632 during ischemia (sham, control, PMA, Db-cAMP, ischemia-vehicle, hydroxyfasudil-LD, hydroxyfasudil, Y27632-LD, Y27632, Db-cAMP+Rp-cAMP, IP, IP+vehicle, IP+H89, IP+Rp-cAMP, and IP+GF109203X groups, respectively; n=4 or 5 each).

View larger version (48K): [in this window] [in a new window]   Figure 2. Protocols for measuring PKA/Rho-kinase activities. Samples for PKA and Rho-kinase in each group are prepared separately.

We quickly sampled the myocardium in the target region (1) at the end of IP, PMA infusion, or db-cAMP infusion to assay PKA and (2) after 60-minute ischemia to assay Rho-kinase activity (Figure 2). The sampled tissues were rapidly frozen in liquid nitrogen and stored at –80°C.

Measurements of Collateral Blood Flow, Risk Area, and Infarct Size
In protocols 1 and 2, we measured the myocardial collateral blood flow after 60 minutes of ischemia by a nonradioactive microsphere method and evaluated both the area at risk and the infarct size by dual staining, as described previously.^6,10

Exclusion Criteria
To ensure that all of the animals included in the data analysis were healthy and were exposed to a similar extent of ischemia, the exclusion criteria described previously¹⁰ regarding hemodynamism, excessive collateral flow, and lethal arrhythmia were used.

PKA and Rho-Kinase Assay
We assayed PKA and Rho-kinase activity as described previously^13,16 with some modifications, using specific antibodies for a substrate of PKA (phospho-CREB [Upstate Biology]) or Rho-kinase (myosin phosphatase targeting subunit [MYPT]-1 [Upstate Biotechnology]) and phospho-MYPT-1 [Thr696; Upstate Biotechnology]) as the primary antibodies. Rho-kinase activity was determined as the phosphorylated ratio of MYPT.

Statistical Analysis
Results are expressed as mean±SEM. Statistical analysis was performed by ANOVA with modified Bonferroni’s post hoc test, and significance was defined at P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Mortality and Exclusions, Hemodynamic Parameters, Risk Area, and Collateral Blood Flow
Among the 242 dogs used in protocols 1 and 2, 55 dogs met the exclusion criteria of ventricular fibrillation or excessive myocardial collateral blood flow (>15 mL/100 g per min). Therefore, 187 dogs completed these protocols satisfactorily and were included in the data analysis (Table). The changes of ABP and HR were comparable among the 23 groups throughout the experiment (data not shown), and the area at risk and collateral blood flow were also comparable (Table).

View this table: [in this window] [in a new window]   Profile of the Groups in Protocols 1 and 2

Infarct Size
Figure 3 shows the infarct size for each group in protocol 1 (left) and protocol 2 (right). In protocol 1, IP (11.9±2.1% in the IP group and 14.8±2.1% in the IP+vehicle group) as well as preischemic treatment with PMA and Db-cAMP in combination (14.0±2.6% in the PMA+Db-cAMP group) markedly exhibited infarct limitation, which were more potent than either PMA (17.3±2.5%) or db-cAMP (20.1±2.2%) alone but did not reach a significant difference. Infarct size in these 4 groups was significantly smaller (P<0.05 each) than that in either the control (40.1±3.8%) or vehicle (40.6±3.6%) group. Treatment with either H89 or Rp-cAMP during preconditioning similarly blunted the infarct limitation by IP (33.4±3.8% and 34.1±4.1%, respectively; both P<0.05 versus IP and not significant versus control) and db-cAMP (37.4±3.6% and 39.1±3.9%, respectively; both P<0.05 versus the db-cAMP group), whereas these agents did not affect PMA-induced infarct limitation (19.2±3.0% and 18.5±2.7%, respectively; both P<0.05 versus control). Furthermore, infarct limitation by db-cAMP was not affected by the effective dose of GF109203X (20.8±3.1%, P<0.05 each versus control) in this model.⁵ H89, Rp-cAMP, and GF109203X alone did not affect infarct size (42.7±4.2%, 38.6±4.6%, and 41.9±4.5%, respectively) (Figure 3). In protocol 2 (Figure 3, right), administration of the vehicle during ischemia did not influence infarct size (43.4±4.4%), the area at risk, or collateral blood flow (Table 1) compared with the control group. Administration of either hydroxyfasudil or Y27632 during sustained ischemia caused dose-dependent infarct limitation like that attributable to preischemic PKA activation (30.5±5.3% and 22.0±4.1% in the hydroxyfasudil-LD and hydroxyfasudil groups, respectively; 30.0±5.3% and 21.7±3.9% in the Y27632-LD and Y27632 groups, respectively). Only the higher dose of each agent achieved significant (both P<0.05) infarct limitation, showing that these were the minimum doses to exert a sufficient effect in this model. Cytochalasin-D also similarly reduced the infarct size (22.9±4.4%, P<0.05 versus control).

View larger version (32K): [in this window] [in a new window]   Figure 3. Infarct size in the groups in protocols 1 and 2. +P<0.05 vs control. P<0.05 vs IP.

PKA Activity During Preconditioning
In protocol 3, IP and db-cAMP activated PKA (267±22% and 288±34% of baseline, respectively; both P<0.05 versus sham). IP-derived PKA activation was inhibited by coadministration of H89 or Rp-cAMP (112±23% and 99±17%, respectively; both P<0.05 versus IP+vehicle). We also confirmed that Db-cAMP–derived PKA activation was cancelled by Rp-cAMP (121±22%, P<0.05 versus IP+vehicle). Furthermore, we observed that 1 to 5 doses of H89 and Rp-cAMP only caused partial (189±29% and 175±29%, respectively) inhibition of PKA (Figure 4), showing that the dose levels we used in this study were the minimum effective doses, which should eliminate the possibility of a nonspecific action in this model.

View larger version (46K): [in this window] [in a new window]   Figure 4. PKA activity estimated by Western blotting for phosphorylated CREB in protocol 2 (see text for details). Top, Representative specimens; bottom, average values (n=4 to 5 each). +P<0.05 vs sham. P<0.05 vs IP+vehicle.

Rho-Kinase Activity During Ischemia
A 60-minute period of ischemia caused Rho-kinase activation (307±25% of baseline in the control group; P<0.05 versus sham), which was attenuated by IP or preischemic administration of db-cAMP (145±21% and 151±26%, respectively; P<0.05 versus control) but not by PMA (253±30%, P<0.05 versus sham). The IP-induced suppression of Rho-kinase activation was cancelled by Rp-cAMP (247±39%, P<0.05 versus IP) but not by GF109203X (161±34%, P<0.05 versus control) at the same dose as in protocol 1 (Figure 5; left). Furthermore, administration of either hydroxyfasudil or Y27632 during sustained ischemia caused a dose-dependent decrease of Rho-kinase activation (199±36% and 205±33% in the hydroxyfasudil-LD and Y27632-LD groups, respectively; 134±21% and 135±20% in the hydroxyfasudil and Y27632 groups, respectively), which was significant (P<0.05 versus the ischemia-vehicle group) at the higher doses (Figure 5; right).

View larger version (41K): [in this window] [in a new window]   Figure 5. Rho-kinase activity estimated by Western blotting for MYPT-1 and phosphorylated MYPT-1 in protocol 2 (see text for details). Top, Representative specimens; bottom, average values (n=4 to 5 each). +P<0.05 vs sham; P<0.05 vs control.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Triggers of IP: Involvements of cAMP, PKA, and ß-Adrenoceptors
Single or repeated IP as well as repeated treatment with forskolin is reported to rapidly and transiently increase both myocardial cAMP level and tissue PKA activity.⁵ We observed in this model that the intracoronary coadministration of different types of selective PKA antagonists blunted infarct limitation of IP, suggesting the involvement of PKA in the IP-derived cardioprotection. However, it remains unclear whether the ß-adrenoceptor is involved in this response, despite the prominent role of the ₁-adrenoceptor in PKC-mediated cardioprotection.^1,5 Although a single exposure to brief ischemia or a ß-agonist limits infarct size through ß-adrenoceptor activation^5,17 and repeated preischemic activation of the cAMP-PKA–dependent pathway is also modulated by ß-adrenoceptor expression,¹⁸ the contribution of this receptor in cardioprotection by repeated exposures remains unclear^5,17 because of PKA-induced rapid desensitization.¹⁹ It is reported in other systems that the repeated IP might lead to cAMP accumulation and direct PKA activation independently of the ß-adrenoceptor⁵ through the inhibition of phosphodiesterase⁵ or direct sensitization of adenylate cyclase.²⁰ However, we have documented preliminarily in the present model that the intracoronary coadministration of the selective ultra-short-acting ß₁-adrenoceptor blocker landiolol²¹ around the preconditioning ischemia (as in protocol 1) blunted the infarct limitation by IP used in this study (35.0±4.4%, n=7) as well as PKA inhibitors during IP, additionally suggesting the essential contribution of ß₁-adrenoceptor activation to cause IP-induced PKA-dependent cardioprotection in this model. However, more studies might be expected to clarify these issues.

On the other hand, IP leads to decreased cAMP accumulation during sustained ischemia,²² but it is controversial whether this explains the cardioprotection afforded by preischemic activation of PKA.^5,22 Enhancement of cAMP accumulation during sustained ischemia fails to block cardioprotection by IP.²² Moreover, overexpression of ß-adrenergic receptor kinase-1, which causes functional uncoupling of ß-adrenoceptors, impairs ischemia-reperfusion injury, and this impairment is reversed by co-overexpression of ß-adrenergic receptor kinase-1 inhibitor.²³

Role of PKA and PKC
Manganello et al⁸ demonstrated that PKA primarily phosphorylates the switch-I region of G-₁₃ (an essential G-protein for signaling to RhoA stimulated by G-protein–coupled receptors⁸) and inhibits its binding with G-ß-, which subsequently leads to the inhibition of G-₁₃ turnover and inactivation of RhoA.

Although PKC²⁴ or its downstream kinase²⁵ has been reported to induce actin assembly through activation of PKC-potentiated phosphatase inhibitor and Rho-kinase, another study found that both PKC and the downstream Src tyrosine kinase rapidly deactivate RhoA through p190 and cause actin disassembly.²⁶ The PKC-Src/Lck pathway was reported to play a role in cardioprotection by IP.⁴ However, preischemic PKC activation had little influence on IP-induced Rho-kinase inhibition in this study, showing the limited contribution of PKC to this pathway. Furthermore, we have reported²⁷ that Src/Lck tyrosine kinase is not involved in the infarct limitation by IP in this model. Although it did not reach statistical significance, our present data additionally imply that (1) there are multiple pathways in parallel to confer cardioprotection of IP, PKC-induced Rho-kinase–independent and PKA-induced Rho-kinase–dependent ones, or (2) PKC-induced pathway exerts stronger effects than the PKA-induced one to cause cardioprotection of IP. Given that repeated IP only promotes transient, not sustained, activation of PKC,²⁸ it is highly possible that transient activation of both PKA and PKC is independently but synergistically responsible for mediating a variety of cardioprotective pathways triggered by IP.

Cardioprotection by Rho-Kinase Inhibition
Because inhibition of Rho-kinase directly relaxes vascular smooth muscle,^9,13,29 it may increase regional myocardial blood flow at sites of major coronary artery stenosis (without any inotropic or chronotropic effect) by dilating the abnormal artery.²⁹ However, this study showed that Rho-kinase inhibition during sustained ischemia exerted cardioprotection without altering hemodynamics, even after all of the dogs with excessive collateral flow were excluded from analysis. Therefore, the infarct-limiting mechanism that involves Rho-kinase inhibition could be independent of either a change in systemic hemodynamics or the recruitment of collateral blood flow.

Rho-kinase has multiple effects on the cardiovascular system, which dominantly represent those of RhoA,⁹ because of inhibition of myosin phosphatase and activation of the ERM family (ezrin, radixin, or moesin) or adducin.⁹ Importantly, Rho-kinase plays a major role in stress fiber formation, focal adhesion, migration, and cytokinesis through activation of the ERM family and thus can enhance cardiac damage in acute ischemia. The potent infarct limitation by cytochalasin-D that mimicked PKA–Rho-kinase–mediated cardioprotection suggests that deactivation of stress fiber polymerization is a major part of this cardioprotective mechanism.

In fact, the effect of changes to the actin cytoskeleton on infarct size has been controversial, because a previous study revealed that targeted deletion of the internal actin disruptor caused the exacerbation of ischemic damage and was rescued by cytochalasin-D,³⁰ whereas another study revealed that cytochalasin-D abolished the infarct limitation by IP.³¹ However, inhibition of Rho and Rho-kinase has also been reported to activate endothelial NO synthase,¹⁵ K_ATP channels,³² and 5'-nucleotidase,³³ all of which have been reported to protect the myocardium against ischemia-reperfusion injury. Additional studies are needed to clarify such issues, because these controversies are likely to be attributable to the differences in experimental design and in the critical time window for the contribution of each factor.

Inhibition of Rho-kinase has also been shown to attenuate the production of superoxide, reduce the generation of monocyte chemoattractant protein-1 or plasminogen activator inhibitor-1, and inhibit the activation of macrophages, neutrophils, and platelets, all of which finally lead to the inhibition of stress-induced regional inflammatory responses and diminished myocardial ischemia-reperfusion injury.⁹ IP has been reported to modulate most of these factors,^1,2 additionally supporting our present results. Accordingly, our preliminary data in the same model indicate that the intracoronary infusion of Y27632 (3 µg/kg per min) for 30 minutes just after reperfusion also reduced infarct size (22.3±4.8%, n=7) as expected. However, the underlying mechanism and its association with the IP-induced preischemic PKA activation should be further elucidated.

In conclusion, although additional studies will be needed before these can be used for the development of novel, safe, and effective therapies, inhibition of Rho-kinase during ischemia, long-term inhibition of Rho-kinase pharmacologically or genetically, or repeated short-term activation of ß-adrenoceptors or PKA may also be useful.

	Acknowledgments

 
This study was supported by Grants on Human Genome, Tissue Engineering and Food Biotechnology (H13-Genome-11), Grants on Comprehensive Research on Aging and Health (H13-21seiki[seikatsu]-23), Health and Labor Sciences Research from the Ministry of Health, Labor and Welfare, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and in part by Mitsubishi Pharma Research Foundation, the Japan Heart Foundation, and a Grant-in-Aid for JSPS fellows from the Japan Society for the Promotion of Science.

	Footnotes

 
Presented in part at the 76th Scientific Sessions of the American Heart Association, Orlando, FL, November 9–12, 2003, and published as an abstract (Circulation. 2003;108(suppl IV):IV-186).

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Sanada S, Kitakaze M. Ischemic preconditioning: emerging evidence, controversy and translational trials. Int J Cardiol. In press.
   
2. Sanada S, Kitakaze M, Asanuma H, et al. Role of the mitochondrial and sarcolemmal KATP channels in ischemic preconditioning on the canine heart. Am J Physiol Heart Circ Physiol. 2001; 280: H256–H263.[Abstract/Free Full Text]
   
3. Node K, Kitakaze M, Minamino T, et al. Activation of ecto-5'-nucleotidase by protein kinase-C and its role in ischaemic tolerance in the canine heart. Br J Pharmacol. 1997; 120: 273–281.[CrossRef][Medline] [Order article via Infotrieve]
   
4. Ping P, Zhang J, Zheng YT, et al. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. Circ Res. 1999; 85: 542–550.[Abstract/Free Full Text]
   
5. Lochner A, Genade S, Tromp E, et al. Ischemic preconditioning and the beta-adrenergic signal transduction pathway. Circulation. 1999; 100: 958–966.[Abstract/Free Full Text]
   
6. Sanada S, Kitakaze M, Papst PJ, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase-III inhibitors: the role of protein kinase-A and P38 mitogen-activated protein kinase. Circulation. 2001; 104: 705–710.[Abstract/Free Full Text]
   
7. Dong JM, Leung T, Manser E, et al. cAMP-induced morphological changes are counteracted by the activatedRhoA small GTPase and the Rho kinase ROKalpha. J Biol Chem. 1998; 273: 22554–22562.[Abstract/Free Full Text]
   
8. Manganello JM, Huang JS, Kozasa T, et al. Protein kinase A-mediated phosphorylation of the Galpha13 switch-I region alters the Galphabetagamma13-G protein-coupled receptor complex and inhibits Rho activation. J Biol Chem. 2003; 278: 124–130.[Abstract/Free Full Text]
   
9. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2002; 39: 319–327.[CrossRef][Medline] [Order article via Infotrieve]
   
10. Sanada S, Kitakaze M, Papst PJ, et al. Role of phasic dynamism of P38 mitogen-activated protein kinase activation in the ischemic preconditioning on the canine heart. Circ Res. 2001; 88: 175–180.[Abstract/Free Full Text]
    
11. Chijiwa T, Mishima A, Hagiwara M, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5–isoquinoline–sulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990; 265: 5267–5272.[Abstract/Free Full Text]
    
12. Botelho LH, Rothermel JD, Coombs RV, et al. cAMP analog antagonists of cAMP action. Methods Enzymol. 1988; 159: 159–172.[Medline] [Order article via Infotrieve]
    
13. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999; 43: 1029–1039.[Abstract/Free Full Text]
    
14. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997; 389: 990–994.[CrossRef][Medline] [Order article via Infotrieve]
    
15. Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000; 106: 15–24.[Medline] [Order article via Infotrieve]
    
16. Houglum K, Lee KS, Chojkier M. Proliferation of hepatic stellate cells is inhibited by phosphorylation of CREB on serine 133. J Clin Invest. 1997; 99: 1322–1328.[Medline] [Order article via Infotrieve]
    
17. Kovanecz I, Papp JG, Szekeres L. Long-term ischaemic preconditioning of the heart induced by repeated beta-adrenergic stress. Acta Physiol Hung. 1996; 84: 297–298.[Medline] [Order article via Infotrieve]
    
18. Nomura Y, Horimoto H, Mieno S, et al. Repetitive preischemic infusion of phosphodiesterase-III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction. Mol Cell Biochem. 2003; 248: 179–184.[CrossRef][Medline] [Order article via Infotrieve]
    
19. Clark RB, Friedman J, Dixon RA, et al. Identification of a specific site required for rapid heterologous desensitization of the beta-adrenergic receptor by cAMP-dependent protein kinase. Mol Pharmacol. 1989; 36: 343–348.[Abstract]
    
20. Strasser RH, Braun-Dullaeus R, Walendzik H, et al. Alpha 1-receptor-independent activation of protein kinase-C in acute myocardial ischemia: mechanisms for sensitization of the adenylyl cyclase system. Circ Res. 1992; 70: 1304–1312.[Abstract/Free Full Text]
    
21. Motomura S, Hagihara A, Narumi Y, et al. Time course of a new ultrashort-acting beta-adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations. J Cardiovasc Pharmacol. 1998; 31: 431–440.[CrossRef][Medline] [Order article via Infotrieve]
    
22. Sandhu R, Thomas U, Diaz RJ, et al. Effect of ischemic preconditioning of the myocardium on cAMP. Circ Res. 1996; 78: 137–147.[Abstract/Free Full Text]
    
23. Cross HR, Steenbergen C, Lefkowitz RJ, et al. Over-expression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res. 1999; 85: 1077–1084.[Abstract/Free Full Text]
    
24. Watanabe Y, Ito M, Kataoka Y, et al. Protein kinase C-catalyzed phosphorylation of an inhibitory phosphoprotein of myosin phosphatase is involved in human platelet secretion. Blood. 2001; 97: 3798–3805.[Abstract/Free Full Text]
    
25. Jo M, Thomas KS, Somlyo AV, et al. Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J Biol Chem. 2002; 277: 12479–12485.[Abstract/Free Full Text]
    
26. Brandt D, Gimona M, Hillmann M, et al. Protein kinase C induces actin reorganization via a Src- and Rho-dependent pathway. J Biol Chem. 2002; 277: 20903–20910.[Abstract/Free Full Text]
    
27. Kitakaze M, Node K, Asanuma H, et al. Protein tyrosine kinase is not involved in the infarct size-limiting effect of ischemic preconditioning in canine hearts. Circ Res. 2000; 87: 303–308.[Abstract/Free Full Text]
    
28. Simonis G, Weinbrenner C, Strasser RH. Ischemic preconditioning promotes a transient, but not sustained translocation of protein kinase-C and sensitization of adenylyl cyclase. Basic Res Cardiol. 2003; 98: 104–113.[CrossRef][Medline] [Order article via Infotrieve]
    
29. Utsunomiya T, Satoh S, Ikegaki I, et al. Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br J Pharmacol. 2001; 134: 1724–1730.[CrossRef][Medline] [Order article via Infotrieve]
    
30. Endres M, Fink K, Zhu J, et al. Neuroprotective effects of gelsolin during murine stroke. J Clin Invest. 1999; 103: 347–354.[Medline] [Order article via Infotrieve]
    
31. Baines CP, Liu GS, Birincioglu M, et al. Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. Am J Physiol. 1999; 276: H1361–H1368.[Medline] [Order article via Infotrieve]
    
32. Terzic A, Kurachi Y. Actin microfilament disrupters enhance K_ATP channel opening in patches from guinea-pig cardiomyocytes. J Physiol. 1996; 492 (pt 2): 395–404.[Medline] [Order article via Infotrieve]
    
33. Ledoux S, Laouari D, Essig M, et al. Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases. Circ Res. 2002; 90: 420–427.[Abstract/Free Full Text]
    

This article has been cited by other articles:

				H. Nishida, T. Sato, M. Miyazaki, and H. Nakaya Infarct size limitation by adrenomedullin: protein kinase A but not PI3-kinase is linked to mitochondrial KCa channels Cardiovasc Res, January 15, 2008; 77(2): 398 - 405. [Abstract] [Full Text] [PDF]

				S. A. Hamid, H. S. Bower, and G. F. Baxter Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2598 - H2606. [Abstract] [Full Text] [PDF]

				O. C. Manintveld, P. D. Verdouw, and D. J. Duncker The RISK of ROCK Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2563 - H2565. [Full Text] [PDF]

				J. F. Spear, S. K. Prabu, D. Galati, H. Raza, H. K. Anandatheerthavarada, and N. G. Avadhani beta1-Adrenoreceptor activation contributes to ischemia-reperfusion damage as well as playing a role in ischemic preconditioning Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2459 - H2466. [Abstract] [Full Text] [PDF]

				J. N. Peart and G. J. Gross Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1746 - H1753. [Abstract] [Full Text] [PDF]

				D. J. Hausenloy and D. M. Yellon Survival kinases in ischemic preconditioning and postconditioning Cardiovasc Res, May 1, 2006; 70(2): 240 - 253. [Abstract] [Full Text] [PDF]

				D. Garcia-Dorado, A. Rodriguez-Sinovas, M. Ruiz-Meana, J. Inserte, L. Agullo, and A. Cabestrero The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion Cardiovasc Res, May 1, 2006; 70(2): 274 - 285. [Abstract] [Full Text] [PDF]

				J. Inserte, D. Garcia-Dorado, V. Hernando, I. Barba, and J. Soler-Soler Ischemic preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion Cardiovasc Res, May 1, 2006; 70(2): 364 - 373. [Abstract] [Full Text] [PDF]

				H. Shimokawa and A. Takeshita Rho-Kinase Is an Important Therapeutic Target in Cardiovascular Medicine Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1767 - 1775. [Abstract] [Full Text] [PDF]

				A. Robinet, G. Hoizey, and H. Millart PI 3-kinase, protein kinase C, and protein kinase A are involved in the trigger phase of {beta}1-adrenergic preconditioning Cardiovasc Res, June 1, 2005; 66(3): 530 - 542. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 110/1/51    most recent 01.CIR.0000133390.12306.C7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanada, S. Articles by Kitakaze, M. Search for Related Content PubMed PubMed Citation Articles by Sanada, S. Articles by Kitakaze, M. Related Collections Acute myocardial infarction Cardiovascular Pharmacology Animal models of human disease Cell signalling/signal transduction Ischemic biology - basic studies